| Methods |
2‐week placebo run‐in period; inclusion criteria= supine DBP >/= 95 mm Hg after run‐in; 4‐week double‐blind treatment |
| Participants |
All patients: n=40(31 males,9 females); mean age=56.6(9.5) years; baseline BP not reported for all patients |
| Interventions |
Perindopril 2 mg once daily;
Perindopril 4 mg once daily;
Perindopril 8 mg once daily;
Placebo |
| Outcomes |
Supine SBP/DBP using mercury sphygmomanometer |
| Notes |
BP change and SD of change not reported, endpoint BP and endpoint SE reported, calculated endpoint SD from N and endpoint SE, imputed endpoint SD for SD of change; BP data from Figure 2, p. 1133; time of BP measurement not reported (but most likely measured during the first 8 h post‐dose since ambulatory measurements were taken during that period); Jadad score=2; funding source= not reported |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
